Previous Page
11-06/07 :: June/July 2011
nanotimes
Companies Facts
monstrated the scale-up of the manufacturing of both fullerenes and fullerene derivatives. Kg quantities are now available and the production capacity can be easily further increased. Nano-C is a major manuf- acturer of PCBM, currently the most commonly used fullerene derivative, holding an exclusive license for OPV and photodetector applications.”
Dr. Frank Louwet, General Product Manager Ad- vanced Coatings and Chemicals, Agfa Materials will be speaking about „Organic Photovoltaics Devices Based on Orgacon™ PEDOT/PSS.“ “We have been active in OPV from the first beginning in early 2000,” said Dr. Louwet. “Today we are partner in Holst, an open innovation initiative by TNO in the Nether- lands and IMEC in Belgium. One of the objectives of Holst is the development of R2R OLED lighting and OPV. We are also participating in several European programs.”
http://www.opvconference.com N
anometrics Incorporated (NASDAQ: NANO), a provider of advanced process control metrology
systems, announced financial results for its second quarter ended July 2, 2011. Highlights for the quarter include:
• Record revenues of $64.4 million, up 4% sequentially and 27% year-over-year;
• Gross margin of 56.1%, with product gross margin of 57.0% and service gross margin of 51.4%;
• $17.5 million of income from operations and 27.2% operating margin;
• Cash and investments increased by $11.5 million to $91.7 million, after stock repurchases totaling
n
anoMR, Inc., has raised $13 million in equity financing. Excel Venture Management led the
round, joined by Healthcare Ventures, and exi- sting investors vSpring Capital, The Dow Chemical Company, and Sun Mountain Capital. Dr. Steven Gullans of Excel and Gus Lawlor of Healthcare Ven- tures will join the board. The financing will enable nanoMR to develop commercial instruments for the clinical microbiology market, perform clinical studies and prepare for product launch.
“We are extremely excited to partner with Excel and Healthcare Ventures to advance our development of diagnostic products for the clinical microbiology market,” said Victor Esch, nanoMR’s CEO. “Our new
$4.3 million during the quarter;
• Continued competitive wins, increased traction of the UniFire system for advanced wafer-scale packaging, and further growth of our integrated metrology and materials characterization businesses.
For the third quarter of 2011, management expects revenues in the range of $57 to $60 million, gross margin in the range of 52% to 53% and operating income in the range of 19% to 21% of revenues. Management expects operating expenses in the third quarter of 2011 to be up $0.1 to $0.3 million from the second quarter of 2011 and an anticipated effec- tive income tax rate of approximately 35%. Taking these factors into account, management expects net earnings for the third quarter of 2011 in the range of $0.28 to $0.34 per diluted share.
43